Valneva (VLA) investor relations material

Executive summary

• Q1 2026 revenues were €30.9 million, down from €49.2 million in Q1 2025, mainly due to the wind-down of third-party product sales and shipment phasing differences to the U.S. Department of Defense.

• Net loss widened to €32.1 million from €9.2 million year-over-year, impacted by one-off effects in cost of goods, idle costs, and lower sales.

• Cash position at March-end was €105.3 million, excluding €37 million from a reserved offering completed in April.

• Major cost reduction program launched, including a 10–15% global workforce reduction and a targeted 25–35% cut in operating expenses versus 2025.

• Pfizer plans 2026 regulatory filings for the Lyme disease vaccine after strong Phase 3 efficacy (>70%) but only the second pre-specified statistical criterion was met.

Financial highlights

• Product sales were €30.5 million, down from €48.6 million in Q1 2025, reflecting a 97.6% reduction in third-party product sales.

• Operating loss was €23.7 million, with a net loss of €32.1 million compared to €9.2 million in the prior year.

• Adjusted EBITDA loss was €18.2 million, compared to a loss of €0.6 million in Q1 2025.

• Gross margin on commercial product sales (excluding IXCHIQ) was 45.1%, down from 62.7% in Q1 2025, due to higher manufacturing costs and one-time effects.

• Cash and cash equivalents at March 31, 2026, were €105.3 million.

Outlook and guidance

• Product sales guidance for 2026 revised to €135–150 million, and total revenues to €145–160 million, reflecting adverse travel vaccine trends.

• Operating expenses expected to decrease by 25–35% in 2026 compared to 2025, driven by restructuring and workforce reduction.

• Product gross margins expected to normalize after Q1 one-off effects.

• Commercial business expected to remain cash-flow positive.

• Potential for financial self-sustainability in 2027, contingent on Lyme vaccine approval and commercialization.